Dr. Schiff joined Aisling in 2000 and serves as one of the Managing Partners. Prior to
Aisling, Dr. Schiff practiced internal medicine for six years at the New York Presbyterian
Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine.
Dr. Schiff currently serves as a director of Aclaris Therapeutics and Monte Rosa
Therapeutics. His prior board service includes Adams Respiratory Therapeutics (acquired by
Reckitt Benckiser), Agile Therapeutics, ArgiNOx Pharmaceuticals, ARMGO Pharma, Barrier
Therapeutics (acquired by Stiefel Laboratories), Bioenvision (acquired by Genzyme),
CardioKine (acquired by Cornerstone), Cempra Pharmaceuticals, F2G, Harmony Biosciences,
Miramar Labs (acquired by Sientra), Myogen (acquired by Gilead Sciences), PowerVision
(acquired by Alcon), Quintiles (now IQVIA), SkinMedica (acquired by Allergan), Sirion
Therapeutics (licenses acquired by Alcon), TransEnterix, Zavante Therapeutics (acquired by
Nabriva) and ZELTIQ Aesthetics (acquired by Allergan). He is a longtime supporter and board
member of the Visiting Nurse Service of New York.
Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from
Columbia Business School, and his B.S. with honors in Neuroscience from Brown University.